Details
Patients with inflammatory bowel disease (IBD) increasingly use cannabis. Studies investigating the effectiveness and safety of cannabis as a therapeutic option for IBD have reported conflicting findings, and recent reviews have not incorporated evidence from real-world studies. This systematic review assessed controlled non-interventional studies and interventional trials evaluating the effectiveness of delta-9-tetrahydrocannabinol (THC)-containing cannabis products in patients with IBD.
The systematic review procedures-including search strategy across four databases, literature screening, data extraction, qualitative result synthesis, and risk of bias assessment-followed the Cochrane Handbook and adhered to PRISMA-compliant reporting. We used the GRADE approach to rate evidence quality for each outcome.
Additional Information
Contributors
Sebastian Jugl, Silvia Perez-Vilar, Steven Galati, Sukhminder K. Sandhu, Hung-Kai Chen, Shao-Hsuan Chang, Yehua Wang, Thorben Kurzbach, Lauren Adkins, Jingchuan Guo, Yan Wang, Almut G. Winterstein, Amie Goodin